Thu, Nov 20, 2014, 4:02 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Ocata Therapeutics, Inc. Message Board

ipstissueface 47 posts  |  Last Activity: Nov 3, 2014 4:29 PM Member since: Oct 25, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Biotime quietly building a next-gen biotech empire, gonna EXPLODE in 2015 with release of LifeMap medical app and cancer diagnostic products.

    BioTime’s Subsidiary Cell Cure Neurosciences Receives FDA Authorization to Initiate Phase I/IIa Trial of Embryonic Stem Cell-Derived OpRegen® for the Treatment of the Dry Form of Age-Related Macular Degeneration
    IND cleared for Phase I/IIa dose escalation trial in patients with the dry form of age-related macular degeneration (AMD) called geographic atrophy (GA)
    No approved therapy exists for dry-AMD, the leading cause of visual impairment in an aging population in the US and other developed countries
    OpRegen® will be the first preparation of xeno-free human embryonic stem cell-derived RPE cells evaluated for transplant therapy of dry-AMD.

  • Top scientist desperately trying to get in the hESC game.....Maybe he can talk to Dr. west to help him?

    The U.S. Supreme Court will be asked to intervene over a controversial embryonic stem cell patent, opponents of the patent said Thursday.

    Jeanne Loring, a stem cell scientist at The Scripps Research Institute, said the court will be asked Friday to overturn a lower court decision and allow the opponents to seek cancellation of the patent held by the Wisconsin Alumni Research Foundation, or WARF.

    Document set

    WARF HESC patent challenge

    Challenge to WARF HESC patent
    Loring and two public interest groups, Consumer Watchdog and the Public Patent Foundation, have been trying to get that patent overturned since 2006. Another patent giving rights over induced pluripotent stem cells has been waived by WARF.

    Loring, who is researching the use of induced pluripotent stem cells to treat Parkinson's disease, said the remaining patent impedes development of embryonic stem cell therapies.

    Embryonic stem cell therapies are reaching the clinical stage, such as San Diego's ViaCyte, which recently began trials of its therapy for Type 1 diabetes, derived from human embryonic stem cells.

    "We think that now embryonic stem cells really are showing their worth in clinical studies, it's very important to just wipe this thing off the books, so nobody can either shut down trials or require huge licensing fees for successful efforts," Loring said.

    The foundation got the patent for work by James Thomson of the University of Wisconsin-Madison. He was the first to derive human embryonic stem cells, in 1998.

    Opponents say Thomson's feat, while significant, was not a patent-worthy technological advance. Loring has said other qualified scientists could have isolated the cells with methods used for finding animal embryonic stem cells, so the

  • Reply to

    Biotime next 6 months

    by btimnextmicrosoft Oct 28, 2014 4:43 PM
    ipstissueface ipstissueface Oct 28, 2014 6:23 PM Flag

    OrthoCyte now has over 40 orthopedic stem cell lines. Expect an IPO in late 2015 when preclinical results come in as well as near term ceramic/HyStem 'device' gets EU/FDA clearance.

  • ipstissueface ipstissueface Oct 16, 2014 9:48 PM Flag

    Major pop coming!

  • LifeMaps and OncoCyte next in line

    Sentiment: Strong Buy

  • ipstissueface by ipstissueface Oct 6, 2014 7:52 PM Flag

    Nice!

  • Reply to

    I can't believe people aren't

    by cutugno Oct 6, 2014 2:59 PM
    ipstissueface ipstissueface Oct 6, 2014 3:07 PM Flag

    Don't think twice just buy at these levels, BTX will make mainstream news next year when cancer diagnostic products come to market, at that time they will be upgraded, a topic of conversation on shows like Cramers Mad Money and will be triple the price.

  • ipstissueface by ipstissueface Oct 6, 2014 2:16 PM Flag

    Last heard, positive safety trial in Spain:

    I Renevia™ Appears Safe And Well Tolerated With No Serious Unexpected Adverse Events Observed During The Trial Period Manufacturing and Biocompatibility Information Submitted in a Device Master File to FDA

    ALAMEDA, Calif., Jan 13, 2014 (BUSINESS WIRE) -- BioTime, Inc. (nyse mkt:BTX) today announced the completion of a safety trial evaluating Renevia™, a proprietary injectable matrix designed to facilitate the stable engraftment of transplanted cells, and the results of that study.

  • ACTC's AMD product is animal based :(
    BTX's is Zeno free :)

  • ipstissueface by ipstissueface Oct 6, 2014 1:52 PM Flag

    “We are pleased with the quality of our growing number of institutional investors,” said Dr. Michael D. West, BioTime’s CEO. “This new capital raise, coupled with capital raised and clinical trial grants to our subsidiary Asterias Biotherapeutics, Inc. this year, will strengthen our capabilities as we and our subsidiaries advance our seven clinical-stage product development programs through what we anticipate will be important inflection points on the path to value creation for our shareholders.”

  • ipstissueface by ipstissueface Oct 6, 2014 1:46 PM Flag

    Mr. Mulroy served in various capacities during his tenure from January 2011 to September 2014, including as Executive Vice President – Strategic Affairs, Chief Financial Officer, General Counsel, and Corporate Secretary. During the time Mr. Mulroy worked at Questcor, the company’s stock price rose more than 500%.

  • ipstissueface ipstissueface Oct 4, 2014 12:33 AM Flag

    PanC lung, bladder and breast cancer diagnostics out next year but first OncoCyte will IPO.
    Dr. West is genius!

  • ipstissueface ipstissueface Oct 2, 2014 2:08 PM Flag

    Here we go....back up to $10 when PanC unveiled in 4th quarter along with huge increase in revenues.

  • Dow headed back up after war and Ebola fears subsided in the days ahead. PanC-DX to set new standard of cancer diagnostics.....ready to ring in the New Year!

    Sentiment: Strong Buy

  • ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 1, 2014-- BioTime, Inc. (NYSE MKT:BTX) and its subsidiary LifeMap Solutions, Inc., a medical technology company, today announced significant additions to the LifeMap Solutions management team. LifeMap Solutions is partnering with the Icahn Institute at Mount Sinai to create innovative mobile health (mHealth) products and services backed by big data. Today the company announced the appointment of Rafhael Cedeno as Chief Technology Officer and Head of Product, as well as the addition of Joel Dudley, PhD, Rong Chen, PhD, and Elissa Levin from the Icahn Institute as members of the LifeMap Solutions science team.

    A veteran in big data and consumer technology applications, Rafhael Cedeno comes to LifeMap Solutions with significant experience at Internet and software companies, including his previous role as Vice President of Game Development for Viacom, where he oversaw the development of top-charting iOS and Android apps on the Apple App Store and Google Play, respectively, and provided technical and product direction for other projects at Viacom. Earlier in his career, Mr. Cedeno worked at such influential Internet companies as Netscape and Kontiki. As Chief Technology Officer and Head of Product, Mr. Cedeno will be responsible for overseeing all aspects of product development, including the integration of Mount Sinai's expertise and data into LifeMap Solutions' products.

    "Adding Rafhael Cedeno to our team is a major win for us," said LifeMap Solutions CEO Corey Bridges. "He brings to LifeMap Solutions his experience architecting and managing the development of complex technology platforms, coupled with the bold innovation he applies to product design. His history of success in the mobile space meshes perfectly with our needs."

    "This is an exciting time to work in health technology. We are living in an era characterized by an unprecedented ability to analyze enormous quantities of data from sources that weren't easily accessible previously," said Mr. Cedeno. "As we work alongside our partners at Mount Sinai, we are uniquely poised to make an impact in the industry."

    In addition, LifeMap Solutions today announced the names of the new members of the company's science team from their partner, the Icahn Institute at Mount Sinai:

    Joel Dudley, PhD, Director of Biomedical Informatics
    Elissa Levin, MS, CGC, Head of Genomics and Integrative Health Innovations
    Rong Chen, PhD, Director of Clinical Genome Informatics
    Eric Schadt, PhD, founding director of the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai, was previously announced as the leading science advisor to LifeMap Solutions. The science team will coordinate with Mr. Cedeno to share knowledge and expertise to build mHealth products and services.

  • Reply to

    Many will regret not being in this one...-

    by kipk20122 Sep 30, 2014 2:28 PM
    ipstissueface ipstissueface Sep 30, 2014 7:31 PM Flag

    Dr. West stated BTX will achieve multiple milestones by years end, this means LlifeMap App 1.0, multiple PanC-DX products, Renevia ok'd...

  • PanC-DX announcements of positive results/release dates/partners will give us a good pop.
    $9-12 is not out of the question since these products will replace current test within a billion dollar market.

  • Reply to

    Biotime owns 75% of OncoCyte

    by drwestclone Sep 29, 2014 5:41 PM
    ipstissueface ipstissueface Sep 29, 2014 10:28 PM Flag

    Check out the OncoCyte video on the BTX website....PanC-DX has 100 more genetic markers then the current diagnostic tests! Gonna blow the roof off of the industry.

  • ipstissueface by ipstissueface Sep 26, 2014 1:05 AM Flag

    BTX go boom

  • ipstissueface by ipstissueface Sep 25, 2014 9:18 PM Flag

    Mothership BTX is half the price! Cancer diagnostic update Monday. Win-Win

ACTC
6.97+0.17(+2.50%)Nov 13 3:59 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.